All right, Wolf and Sarah, thank you very much and welcome to Fast Money,

I am Brian Sullivan. Hope you're having a great Thursday wherever you may be.

Your traders tonight are Guyadami, Tim Seymour, Karen Finerman, and Stephen Grasso,

so tonight on Fast.

Amazon just keeps amazing on.

The stock hitting another all-time high,

but hasn't come too far too fast

because everybody is buying the same thing.

We're gonna dig in on that.

Also ahead, the banks getting battered again, but one of our traders says this could be one of the

greatest opportunities to get into some long-termterm investments going to tell us why.

And later on a staggering step that you have got to hear around Netflix that stock

continues to be bought as we all binge watch TV. We are going to get to all of that, but we have

got to get to breaking news that is important on the virus and it's also moving the

market after hours. Gilliad Sciences shares, they are surging on some very promising drug news.

Let's get right now to Meg Terrell with more on this big story.

Meg.

Hi Brian, this is breaking news from Stat News. Basically they got a glimpse

from one of the hospitals that has been enrolling patients in a clinical

trial of Gilead's Remdessevere, the University of Chicago.

And essentially what they saw in video communication to faculty members there is a report that

on the clinical trial, it sounds like the patients

...